Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
Giorgio L Colombo,1,2 Sergio Di Matteo,2 Chiara Martinotti,2 Steffen M Jugl,3 Praveen Gunda,4 Mariantonietta Naclerio,5 Giacomo M Bruno2 1Department of Drug Science, Pavia University, Pavia, Italy; 2S.A.V.E. S.r.l. Studi Analisi Valutazioni Economiche Health Economics & Outcomes Research - r...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-08-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/budget-impact-model-of-secukinumab-for-the-treatment-of-moderate-to-se-peer-reviewed-article-CEOR |
| _version_ | 1818701855726764032 |
|---|---|
| author | Colombo GL Di Matteo S Martinotti C Jugl SM Gunda P Naclerio M Bruno GM |
| author_facet | Colombo GL Di Matteo S Martinotti C Jugl SM Gunda P Naclerio M Bruno GM |
| author_sort | Colombo GL |
| collection | DOAJ |
| description | Giorgio L Colombo,1,2 Sergio Di Matteo,2 Chiara Martinotti,2 Steffen M Jugl,3 Praveen Gunda,4 Mariantonietta Naclerio,5 Giacomo M Bruno2 1Department of Drug Science, Pavia University, Pavia, Italy; 2S.A.V.E. S.r.l. Studi Analisi Valutazioni Economiche Health Economics & Outcomes Research - research center, Milan, Italy; 3Novartis Pharma AG, Basel, Switzerland; 4Novartis Healthcare Private Limited, Hyderabad, India; 5Novartis Farma S.p.A, Origgio, Varese, Italy Objective: Secukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes the proinflammatory cytokine IL-17A, has been approved in Europe in 2015 for the treatment of adult patients with moderate-to-severe plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This analysis assessed the budget impact of introduction of secukinumab to the Italian market for all three indications from the perspective of the Italian National Health Service. Materials and methods: A cross-indication budget impact model was developed and included biologic-treated adult patients diagnosed with psoriasis, PsA, and AS. The analyses were conducted over a 3-year time horizon and included direct costs (drug therapy costs, administration costs, diseases-related costs, and adverse events costs). Model input parameters (epidemiology, market share projections, resource use, and costs) were obtained from the published literature and other Italian sources. The robustness of the results was tested via one-way sensitivity analyses: secukinumab cost, secukinumab market share, intravenous administration costs, and adverse events costs were varied by ±10%. Results: The total patient population for secukinumab over the 3-year timeframe was projected to be 6,648 in the first year, increasing to 12,001 in the third year, for all three indications combined (psoriasis, PsA, and AS). Compared to a scenario without secukinumab in the market, the introduction of secukinumab in the market for the treatment of psoriasis, PsA, and AS showed a cumulative 3-year incremental budget impact of -5%, corresponding to savings of €66.1 million and per patient savings of about €1,855. The majority of the cost savings came from the adoption of secukinumab in AS (58%), followed by PsA (29%) and psoriasis (13%). Sensitivity analyses confirmed the robustness of the results. Conclusion: Results from this cross-indication budget impact model show that secukinumab is a cost-saving option for the treatment of PsA, AS, and psoriasis patients in Italy. Keywords: budget impact, psoriasis, psoriatic arthritis, ankylosing spondylitis, Italy, secukinumab |
| first_indexed | 2024-12-17T15:27:28Z |
| format | Article |
| id | doaj.art-4d32083182ca4deeac0c936abff73ad4 |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-12-17T15:27:28Z |
| publishDate | 2018-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-4d32083182ca4deeac0c936abff73ad42022-12-21T21:43:14ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812018-08-01Volume 1047749140189Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiativeColombo GLDi Matteo SMartinotti CJugl SMGunda PNaclerio MBruno GMGiorgio L Colombo,1,2 Sergio Di Matteo,2 Chiara Martinotti,2 Steffen M Jugl,3 Praveen Gunda,4 Mariantonietta Naclerio,5 Giacomo M Bruno2 1Department of Drug Science, Pavia University, Pavia, Italy; 2S.A.V.E. S.r.l. Studi Analisi Valutazioni Economiche Health Economics & Outcomes Research - research center, Milan, Italy; 3Novartis Pharma AG, Basel, Switzerland; 4Novartis Healthcare Private Limited, Hyderabad, India; 5Novartis Farma S.p.A, Origgio, Varese, Italy Objective: Secukinumab, a fully human monoclonal IgG1 antibody that selectively neutralizes the proinflammatory cytokine IL-17A, has been approved in Europe in 2015 for the treatment of adult patients with moderate-to-severe plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This analysis assessed the budget impact of introduction of secukinumab to the Italian market for all three indications from the perspective of the Italian National Health Service. Materials and methods: A cross-indication budget impact model was developed and included biologic-treated adult patients diagnosed with psoriasis, PsA, and AS. The analyses were conducted over a 3-year time horizon and included direct costs (drug therapy costs, administration costs, diseases-related costs, and adverse events costs). Model input parameters (epidemiology, market share projections, resource use, and costs) were obtained from the published literature and other Italian sources. The robustness of the results was tested via one-way sensitivity analyses: secukinumab cost, secukinumab market share, intravenous administration costs, and adverse events costs were varied by ±10%. Results: The total patient population for secukinumab over the 3-year timeframe was projected to be 6,648 in the first year, increasing to 12,001 in the third year, for all three indications combined (psoriasis, PsA, and AS). Compared to a scenario without secukinumab in the market, the introduction of secukinumab in the market for the treatment of psoriasis, PsA, and AS showed a cumulative 3-year incremental budget impact of -5%, corresponding to savings of €66.1 million and per patient savings of about €1,855. The majority of the cost savings came from the adoption of secukinumab in AS (58%), followed by PsA (29%) and psoriasis (13%). Sensitivity analyses confirmed the robustness of the results. Conclusion: Results from this cross-indication budget impact model show that secukinumab is a cost-saving option for the treatment of PsA, AS, and psoriasis patients in Italy. Keywords: budget impact, psoriasis, psoriatic arthritis, ankylosing spondylitis, Italy, secukinumabhttps://www.dovepress.com/budget-impact-model-of-secukinumab-for-the-treatment-of-moderate-to-se-peer-reviewed-article-CEORBudget impactPsoriasisPsoriatic ArthritisAnkylosing spondylitisItalysecukinumab |
| spellingShingle | Colombo GL Di Matteo S Martinotti C Jugl SM Gunda P Naclerio M Bruno GM Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative ClinicoEconomics and Outcomes Research Budget impact Psoriasis Psoriatic Arthritis Ankylosing spondylitis Italy secukinumab |
| title | Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative |
| title_full | Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative |
| title_fullStr | Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative |
| title_full_unstemmed | Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative |
| title_short | Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative |
| title_sort | budget impact model of secukinumab for the treatment of moderate to severe psoriasis psoriatic arthritis and ankylosing spondylitis in italy a cross indication initiative |
| topic | Budget impact Psoriasis Psoriatic Arthritis Ankylosing spondylitis Italy secukinumab |
| url | https://www.dovepress.com/budget-impact-model-of-secukinumab-for-the-treatment-of-moderate-to-se-peer-reviewed-article-CEOR |
| work_keys_str_mv | AT colombogl budgetimpactmodelofsecukinumabforthetreatmentofmoderatetoseverepsoriasispsoriaticarthritisandankylosingspondylitisinitalyacrossindicationinitiative AT dimatteos budgetimpactmodelofsecukinumabforthetreatmentofmoderatetoseverepsoriasispsoriaticarthritisandankylosingspondylitisinitalyacrossindicationinitiative AT martinottic budgetimpactmodelofsecukinumabforthetreatmentofmoderatetoseverepsoriasispsoriaticarthritisandankylosingspondylitisinitalyacrossindicationinitiative AT juglsm budgetimpactmodelofsecukinumabforthetreatmentofmoderatetoseverepsoriasispsoriaticarthritisandankylosingspondylitisinitalyacrossindicationinitiative AT gundap budgetimpactmodelofsecukinumabforthetreatmentofmoderatetoseverepsoriasispsoriaticarthritisandankylosingspondylitisinitalyacrossindicationinitiative AT nacleriom budgetimpactmodelofsecukinumabforthetreatmentofmoderatetoseverepsoriasispsoriaticarthritisandankylosingspondylitisinitalyacrossindicationinitiative AT brunogm budgetimpactmodelofsecukinumabforthetreatmentofmoderatetoseverepsoriasispsoriaticarthritisandankylosingspondylitisinitalyacrossindicationinitiative |